CA2683980A1 - Topical composition comprising n-acetylaldosamines or n-acetylamino acids - Google Patents

Topical composition comprising n-acetylaldosamines or n-acetylamino acids Download PDF

Info

Publication number
CA2683980A1
CA2683980A1 CA002683980A CA2683980A CA2683980A1 CA 2683980 A1 CA2683980 A1 CA 2683980A1 CA 002683980 A CA002683980 A CA 002683980A CA 2683980 A CA2683980 A CA 2683980A CA 2683980 A1 CA2683980 A1 CA 2683980A1
Authority
CA
Canada
Prior art keywords
acetyl
agents
skin
acid
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002683980A
Other languages
French (fr)
Other versions
CA2683980C (en
Inventor
Ruey J. Yu
Eugene J. Van Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22852222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2683980(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA2778317A priority Critical patent/CA2778317C/en
Publication of CA2683980A1 publication Critical patent/CA2683980A1/en
Application granted granted Critical
Publication of CA2683980C publication Critical patent/CA2683980C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Abstract

Compositions comprising N-acetyl-aldosamines, N-acetylamino acids, and related N--acetyl compounds are useful to alleviated or improve various cosmetic conditions and dermatological disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors. N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl composition may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.

Claims (53)

WHAT WE CLAIM IS:
1. A composition comprising (A) a topically acceptable vehicle for topical treatment of cosmetic conditions or dermatological disorders and (B) a therapeutically effective amount of at least one N-acetyl aldosamine selected from the group consisting of N-acetyl-glycerosamine, N-acetyl-erythrosamine, N-acetyl-threosamine, N-acetyl-ribosamine, N-acetyl-arabinosamine, N-acetyl-xylosamine, N-acetyl-lyxosamine, N-acetyl-allosamine, N-acetyl-altrosamine, N-acetyl-gulosamine, N-acetyl-idosamine, N-acetyl-talosamine, N-acetyl-glucoheptosamine, N-acetyl-galactoheptosamine, N-acetyl-mannoheptosamine, N-acetyllactosamine, N-acetyl-glyceraminic acid, N-acetyl-erythrosaminic acid, N-acetyl-threosaminic acid, N-acetyl-ribosaminic acid, N-acetyl-arabinosaminic acid, N-acetyl-xylosaminic acid, N-acetyl-lyxosaminic acid, N-acetyl-allosaminic acid, N-acetyl-altrosaminic acid, N-acetyl-glucosaminic acid, N-acetyl-mannosaminic acid, N-acetyl-gulosaminic acid, N-acetyl-idosaminic acid, N-acetyl-galactosaminic acid, N-acetyl-talosaminic acid, N-acetyl-heptoglucosaminic acid, N-acetyl-heptogalactosaminic acid, N-acetyl-heptomannosaminic acid, and isomeric or nonisomeric, free acid, salt, lactone, amide, and ester forms thereof.
2. The composition of claim 1, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, nail and hair, conditions and disorders selected from dryness of or looseness of skin, nail and hair, xerosis, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, uneven and rough surfaces of skin, nail and hair, dandruff, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, nail plate and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair lubricants and luster, and fragility and splitting of nails and hair.
3. The composition of claim 1 , further comprising (C) a cosmetic, pharmaceutical or other topical agent.
4. The composition of claim 3 , wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of agents that improve or eradicate age spots, keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents.
5. The composition of claim 4 , wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid,l3-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, salicylic acid, vitamin E and vitamin E acetate.
6. A composition comprising (A) a topically acceptable vehicle for topical treatment of cosmetic conditions or dermatological disorders and (B) a therapeutically effective amount of at least one compound selected from the group consisting of N-acetyl-isoleucine, N-acetyl-threonine, N-acetyl-histidine, N-acetyl-taurine, N-acetyl-canavanine, N-acetyl-hydroxylysine, N-acetyl-cycloserine, N-acetyl-homoarginine, N-acetyl-norleucine, N-acetyl-norvaline, N-acetyl-homoserine, N-acetyl-methylserine, N-acetyl-hydroxyvaline, N-acetyl-ethionine, N-acetyl-methoxinine, N-acetyl-.beta.-aminoisobutanoic acid, N-acetyl-homophenylalanine, N-acetyl-homotryptophan, N-acetyl-5-hydroxytryptamine (N-acetyl-ethionine, N-acetyl-methoxinine, N-acetyl-.beta.-aminoisobutanoic acid, N-acetyl-homophenylalanine, N-acetyl-homotryptophan, N-acetyl-5-hydroxytryptamine (N-acetyl-serotonin), N-acetyltryptamine, N-acetyl-ornithine, N-acetyl-citrulline, N-acetyl-argininosuccinic acid, N-acetyl-dopa, N-acetyl-3-iodotyrosine, N-acetyl-3,5-diiodotyrosine, N-acetyl-3,5,3'-triiodothyronine, N-acetyl-thyroxine, N-acetyl-creatine, N-acetyl-creatinine, isomeric or nonisomeric, free acid, salt, lactone, amide, and ester forms thereof.
7. The composition of claim 6 , wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, nail and hair, conditions and disorders selected from dryness of or looseness of skin, nail and hair, xerosis, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, uneven and rough surfaces of skin, nail and hair, dandruff, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, nail plate and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair lubricants and luster, and fragility and splitting of nails and hair.
8. The composition of claim 6 further comprising (C) a cosmetic, pharmaceutical or other topical agent.
9. The composition of claim 8 wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of agents that improve or eradicate age spots, keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents.
. The composition of claim 9 , wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, and salicylic acid.
11. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a topically acceptable vehicle and (B) a therapeutically effective amount of at least one N-acetyl aldosamine selected from the group consisting of N-acetyl-galactosamine[,] and N-acetyl-mannosamine, as isomeric or nonisomeric, free acid or salt forms thereof;

wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of ichthyosis, lichen simplex chronicus, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, melasmas, hyperpigmented skin, and stretch marks.
12. Use for treating cosmetic conditions and dermatological disorders of a composition comprising: (A) a topically acceptable vehicle; (B) a therapeutically effective amount of at least one N-acetyl aldosamine selected from the group consisting of N-acetyl-galactosamine[,] and N-acetyl-mannosamine as isomeric or nonisomeric, free acid or salt form thereof; and (C) a cosmetic, pharmaceutical or other topical agent selected from the group consisting of local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, skin lightening agents, depigmenting agents, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of ichthyosis, lichen simplex chronicus, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, melasmas, hyperpigmented skin, and stretch marks.
13. The use of claim 12, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, and salicylic acid.
14. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a topically acceptable vehicle and (B) a therapeutically effective amount of at least one N-acetyl aldosamine selected from the group consisting of N-acetyl-glycerosamine, N-acetyl-erythrosamine, N-acetyl-threosamine, N-acetyl-ribosamine, N-acetyl-arabinosamine, N-acetyl-xylosamine, N-acetyl-lyxosamine, N-acetyl-allosamine, N-acetyl-altrosamine, N-acetyl-idosamine, N-acetyl-talosamine, N-acetyl-glucoheptosamine, N-acetyl-galactoheptosamine, N-acetyl-mannoheptosamine, N-acetyllactosamine, N-acetyl-glyceraminic acid, N-acetyl-erythrosaminic acid, N-acetyl-threosaminic acid, N-acetyl-ribosaminic acid, N-acetyl-arabinosaminic acid, N-acetyl-xylosaminic acid, N-acetyl-lyxosaminic acid, N-acetyl-allosaminic acid, N-acetyl-altrosaminic acid, N-acetyl-glucosaminic acid, N-acetyl-gulosaminic acid, N-acetyl-idosaminic acid, N-acetyl-talosaminic acid, N-acetyl-heptoglucosaminic acid, N-acetyl-heptogalactosaminic acid, N-acetyl-heptomannosaminic acid, and isomeric or nonisomeric, free acid, salt, lactone, amide, and ester forms thereof;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, nail and hair, conditions and disorders selected from dryness of or loosness of skin, nail and hair, xerosis, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, uneven and rough surfaces of skin, nail and hair, dandruff, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, nail plate and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair lubricants and luster, and fragility and splitting of nails and hair.
15. The use of claim 14, wherein the composition further comprises (C) a cosmetic, pharmaceutical or other topical agent.
16. The use of claim 15, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of agents that improve or eradicate age spots, keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antisebonheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents.
17. The use of claim 16, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21 -acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, salicylic acid, vitamin E and vitamin E acetate.
18. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a topically acceptable vehicle and (B) a therapeutically effective amount of at least one compound, selected from the group consisting of N-acetyl-valine, N-acetyl-isoleucine, N-acetyl-threonine, N-acetyl-histidine, N-acetyl-taurine, N-acetyl-canavanine, N-acetyl-hydroxylysine, N-acetyl-cycloserine, N-acetyl-homoarginine, N-acetyl-norleucine, N-acetyl-norvaline, N-acetyl-homoserine, N-acetyl-methylserine, N-acetyl-hydroxyvaline, N-acetyl-ethionine, N-acetyl-methoxinine, N-acetyl-.beta.-aminoisobutanoic acid, N-acetyl-cysteine sulfinic acid, N-acetyl-homophenylalanine, N-acetyl-homotryptophan, N-acetyl-5-hydroxytryptamine (N-acetyl-serotonin), N-acetyltryptamine, N-acetyl-omithine, N-acetyl-citrulline, N-acetyl-argininosuccinic acid, N-acetyl-dopa, N-acetyl-3-iodotyrosine, N-acetyl-3,5-diiodotyrosine, N-acetyl-3,5,3'-triiodothyronine, N-acetyl-thyroxine, N-acetyl-creatine, N-acetyl-creatinine, N-acetyl-homocystine, isomeric or nonisomeric, free acid, salt, lactone, amide, and ester forms thereof;

wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, nail and hair, conditions and disorders selected from dryness of or loosness of skin, nail and hair, xerosis, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, uneven and rough surfaces of skin, nail and hair, dandruff, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, nail plate and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair resiliency, elasticity and recoilability, lack of skin, nail and hair lubricants and luster, and fragility and splitting of nails and hair.
19. The use of claim 18, wherein the composition further comprises (C) a cosmetic, pharmaceutical or other topical agent.
20. The use of claim 19, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of agents that improve or eradicate age spots, keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents.
21. The use of claim 20, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, and salicylic acid.
22. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a topically acceptable vehicle and (B) a therapeutically effective amount of at least one compound, selected from the group consisting of N-acetyl-alanine, N-acetyl-arginine, N-acetyl-asparagine, N-acetyl-aspartic acid, N-acetyl-glutamic acid, N-acetyl-glutamine, N-acetyl-histidine, N-acetyl-isoleucine, N-acetyl-leucine, N-acetyl-lysine, N-acetyl-methionine, N-acetyl-phenylalanine, N-acetyl-serine, N-acetyl-threonine, N-acetyl-tryptophan, N-acetyl-valine, N-acetyl-.beta.-alanine, N-acetyl-.gamma.-aminobutanoic acid, N-acetyl-citrulline, N-acetyl-omithine, N-acetyl-creatine, N-acetyl-creatinine, isomeric or non-isomeric, free acid, salt, lactone, amide, and ester forms thereof;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, uneven and rough surfaces of skin, Darier's disease, lichen simplex chronicus, keratoses, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, skin thickening due to elastosis of photoaging, loss or reduction of skin resiliency, elasticity and recoilability, lack of skin resiliency, elasticity and recoilability, and lack of skin lubricants and luster.
23. The use of claim 22, wherein the composition further comprises (C) a cosmetic, pharmaceutical or other topical agent selected from the group consisting of agents that improve or eradicate age spots, keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents.
24. The use of claim 23, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, salicylic acid, vitamin E and vitamin E acetate.
25. Use for treating cosmetic conditions and dermatological disorders a composition comprising (A) a topically acceptable vehicle and (B) a therapeutically effective amount of at least one compound, selected from the group consisting of N-acetyl-arginine, N-acetyl-asparagine, N-acetyl-glutamic acid, N-acetyl-lysine, N-acetyl-.gamma.-aminobutanoic acid, N-acetyl-ornithine, N-acetyl-creatine, N-acetyl-creatinine, isomeric or non-isomeric, free acid, salt, lactone, amide, and ester forms thereof;

wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, uneven and rough surfaces of skin, Darier's disease, lichen simplex chronicus, keratoses, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, skin thickening due to elastosis of photoaging, loss or reduction of skin resiliency, elasticity and recoilability, lack of skin resiliency, elasticity and recoilability, and lack of skin lubricants and luster.
26. Use for treating cosmetic conditions and dermatological disorders of a composition comprising: (A) a topically acceptable vehicle; (B) a therapeutically effective amount of at least one compound, selected from the group consisting of N-acetyl-arginine, N-acetyl-asparagine, N-acetyl-glutamic acid, N-acetyl-lysine, N-acetyl-.gamma.-aminobutanoic acid, N-acetyl-ornithine, N-acetyl-creatine, N-acetyl-creatinine, isomeric or non-isomeric, free acid, salt, lactone, amide, and ester forms thereof; and (C) a cosmetic, pharmaceutical or other topical agent selected from the group consisting of agents that improve or eradicate age spots, keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, uneven and rough surfaces of skin, Darier's disease, lichen simplex chronicus, keratoses, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, skin thickening due to elastosis of photoaging, loss or reduction of skin resiliency, elasticity and recoilability, lack of skin resiliency, elasticity and recoilability, and lack of skin lubricants and luster.
27. The use of claim 26, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, salicylic acid, vitamin E and vitamin E acetate.
28. Use for treating cosmetic conditions and dermatological disorders of a composition comprising a therapeutically effective amount of N-acetyl-proline, as a free acid, salt, isomeric or nonisomeric forms thereof, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, Darier's disease, lichen simplex chronicus, keratoses, acne, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin and thinning of skin.
29. The use of claim 28, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of acne, eczema, psoriasis, pruritus, age spots, lentigines, melasmas, blemished skin, hyperpigmented skin and thinning of skin.
30. Use for treating cosmetic conditions and dermatological disorders of a composition comprising: (A) a therapeutically effective amount of N-acetyl-proline, as a free acid, salt, isomeric or nonisomeric forms thereof; and (B) a cosmetic, pharmaceutical, or other topical agents, wherein the cosmetic, pharmaceutical, or other topical agent is selected from the group consisting of agents that improve or eradicate age spots, keratoses, local analgesics and anesthetics, antiacne agents, antiyeast agents, antifungal agents, antiviral agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, corticosteroids, tanning agents, hormones, and topical cardiovascular agents;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, Darier's disease, lichen simplex chronicus, keratoses, pseudofolliculitis barbae, eczema, psoriasis, pruritus, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or dimished syntheses of collagen, glycosaminoglycans and proteoglycans, and diminished levels of collagen, glycosaminoglycans, proteoglycans in the dermis.
31. The use of claim 30, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, crotamiton, propranolol, promethazine, and salicylic acid.
32. Use for treating cosmetic conditions and dermatological disorders of a composition comprising a therapeutically effective amount of N-acetyl-proline amide or N-acetyl-proline ester as isomeric or nonisomeric forms thereof, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, nail and hair, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans, and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans, and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, nail plate, and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin, nail, and hair resiliency, elasticity and recoilability, lack of skin, nail, and hair lubricants and luster, and fragility and splitting of nails and hair.
33. Use for treating cosmetic conditions and dermatological disorders of a composition comprising: (A) a therapeutically effective amount of N-acetyl-proline amide or N-acetyl-proline ester as isomeric or nonisomeric form thereof and (B) a cosmetic, pharmaceutical, or other topical agents, wherein the cosmetic, pharmaceutical, or other topical agent is selected from the group consisting of agents that improve or eradicate age spots, keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization, defective syntheses of dermal components, changes associated with aging of skin, nail, and hair, ichthyosis, palmar hyperkeratoses, plantar hyperkeratoses, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, warts, herpes, age spots, lentigines, melasmas, hyperkeratoses, hyperpigmented skin, abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans, and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans, and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, nail plate, and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin, nail, and hair resiliency, elasticity and recoilability, lack of skin, nail, and hair lubricants and luster, and fragility and splitting of nails and hair.
34. The use of claim 33, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, salicylic acid, vitamin E and vitamin E acetate.
35 . The use of claim 32, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of eczema, psoriasis and pruritus.
36. The use of claim32, wherein the N-acetyl-proline ester is selected from the group consisting of N-acetyl-proline methyl ester, N-acetyl-proline ethyl ester, N-acetyl-proline propyl ester, N-acetyl-proline isopropyl ester, N-acetyl-proline butyl ester, N-acetyl-proline amyl ester, N-acetyl-proline hexyl ester and N-acetyl-proline octyl ester.
37. Use for treating cosmetic conditions and dermatological disorders of a composition comprising a therapeutically effective amount of N-acetyl-tyrosine as free acid, salt, lactone, amide, ester, isomeric or nonisomeric forms thereof, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of ichthyosis, palmar and plantar hyperkeratoses, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, hyperkaratoses, abnormal or diminished synthesis of collagen, glycosaminoglycans, proteoglycans, and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans, and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning of skin, nail plate, and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin resiliency, elasticity and recoilability, lack of skin, nail, and hair lubricants and luster, and fragility and splitting of nail and hair.
38. The use of claim 37, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of eczema, psoriasis and pruritus.
39. The use of claim 3 7, wherein the N-acetyl tyrosine is an N-acetyl tyrosine ester selected from the group consisting of N-acetyl-tyrosine methyl ester, N-acetyl-tyrosine ethyl ester, N-acetyl-tyrosine propyl ester, N-acetyl-tyrosine isopropyl ester. N-acetyl-tyrosine butyl ester, N-acetyl-tyrosine amyl ester, N-acetyl-tyrosine hexyl ester and N-acetyl-tyrosine octyl ester.
40. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a therapeutically effective amount of N-acetyl-tyrosine as free acid, salt, lactone, amide, ester, isomeric or nonisomeric form thereof and (B) a cosmetic, pharmaceutical, or other topical agents, wherein the cosmetic, pharmaceutical, or other topical agent is selected from the group consisting of agents that improve or eradicate keratoses and wrinkles, local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antidandruff agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, hair conditioners and hair treatment agents, antiaging and antiwrinkle agents, sunblock and sunscreen agents, skin lightening agents, depigmenting agents, vitamins, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of ichthyosis, palmar and plantar hyperkeratoses, Darier's disease, lichen simplex chronicus, keratoses, acne, pseudofolliculitis barbae, eczema, psoriasis, pruritus, hyperkaratoses, abnormal or diminished synthesis of collagen, glycosaminoglycans, proteoglycans, and elastin, diminished levels of collagen, glycosaminoglycans, proteoglycans, and elastin in the dermis, stretch marks, skin lines, fine lines, wrinkles, thinning or skin, nail plate, and hair, skin thickening due to elastosis of photoaging, loss or reduction of skin resiliency, elasticity and recoilability, lack of skin, nail, and hair lubricants and luster, and fragility and splitting of nail and hair.
41. The use of claim 40, wherein the N-acetyl tyrosine is an N-acetyl tyrosine ester selected from the group consisting of N-acetyl-tyrosine methyl ester, N-acetyl-tyrosine ethyl ester, N-acetyl-tyrosine propyl ester, N-acetyl-tyrosine isopropyl ester, N-acetyl-tyrosine butyl ester, N-acetyl-tyrosine amyl ester, N-acetyl-tyrosine hexyl ester and N-acetyl-tyrosine octyl ester.
42. The use of claim 40, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, monobenzone, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, salicylic acid, vitamin E and vitamin E acetate.
43. Use for treating cosmetic conditions and dermatological disorders of a composition comprising a therapeutically effective amount of N-acetyl-cysteine as free acid, salt, lactone, amide, ester, isomeric or nonisomeric forms thereof, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of Darier's disease, lichen simplex chronicus, pseudofolliculitis barbae, pruritus, warts, and melasmas.
44. The use of claim 43, wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of pruritus and melasmas.
45. The use of claim 43, wherein the N-acetyl cysteine is an N-acetyl-cysteine ester selected from the group consisting of N-acetyl-cysteine methyl ester, N-acetyl-cysteine ethyl ester, N-acetyl-cysteine propyl ester, N-acetyl-cysteine isopropyl ester, N-acetyl-cysteine butyl ester, N-acetyl-cysteine amyl ester, N-acetyl-cysteine hexyl ester and N-acetyl-cysteine octyl ester.
46. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a therapeutically effective amount of N-acetyl-cysteine as free acid, salt, lactone, amide, ester, isomeric or nonisomeric form thereof and (B) a cosmetic, pharmaceutical, or other topical agent, wherein the cosmetic, pharmaceutical, or other topical agent is selected from the group consisting of agents that improve or eradicate keratoses, local analgesics and anesthetics, antiyeast agents, antifungal agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, skin lightening agents, depigmenting agents, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of Darier's disease, lichen simplex chronicus, pseudofolliculitis barbae, pruritus, warts, and melasmas.
47. The use of claim46, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, and salicylic acid.
48. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a topically acceptable vehicle and (B) a therapeutically effective amount of at least one N-acetyl aldosamine selected from the group consisting of N-acetyl-neuraminic acid and N-acetyl-muramic acid as isomeric or nonisomeric, free acid or salt forms thereof;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of ichthyosis, lichen simplex chronicus, pseudofolliculitis barbae, eczema, psoriasis, pruritus, melasmas, hyperpigmented skin, and stretch marks.
49. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a topically acceptable vehicle;
(B) a therapeutically effective amount of at least one N-acetyl aldosamine selected from the group consisting of N-acetyl-neuraminic acid and N-acetyl-muramic acid as isomeric or nonisomeric, free acid or salt form thereof; and (C) a cosmetic, pharmaceutical or other topical agent selected from the group consisting of local analgesics and anesthetics, antiacne agents, antibacterials, antiyeast agents, antifungal agents, antiviral agents, antidermatitis agents, antihistamine agents, antipruritic agents, antiemetics, antimotion sickness agents, antiinflammatory agents, antihyperkeratotic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, skin lightening agents, depigmenting agents, corticosteroids, tanning agents, hormones, retinoids, and topical cardiovascular agents;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of ichthyosis, lichen simplex chronicus, pseudofolliculitis barbae, eczema, psoriasis, pruritus, melasmas, hyperpigmented skin, and stretch marks.
50. The use of claim 49, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole, ketoconazole, miconazole, griseofulvin, econazole, metronidazole, hydroxyzine, diphenhydramine, pramoxine, lidocaine, procaine, mepivacaine, erythromycin, tetracycline, clindamycin, meclocycline, hydroquinone, hydroquinone monoether, minocycline, naproxen, ibuprofen, theophylline, cromolyn, albuterol, retinol, retinyl acetate, retinyl palmitate, retinoic acid, 13-cis retinoic acid, hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone 17-butyrate, betamethasone valerate, betamethasone dipropionate, triamcinolone acetonide, fluocinonide, clobetasol propionate, benzoyl peroxide, crotamiton, propranolol, promethazine, and salicylic acid.
51. Use for treating cosmetic conditions and dermatological disorders of a composition comprising (A) a topically acceptable vehicle and (B) a therapeutically effective amount of N-acetyl-glycine, isomeric or non-isomeric, free acid, salt, lactone, amide, and ester forms thereof;
wherein the cosmetic conditions and dermatological disorders are selected from the group consisting of disturbed keratinization; defective syntheses of dermal components; ichthyosis;
palmar hyperkeratoses; plantar hyperkeratoses; uneven and rough surfaces of skin; Darier's disease; lichen simplex chronicus; keratoses; pseudofolliculitis barbae;
eczema; psoriasis;
pruritus; warts; herpes; age spots; lentigines; melasmas; hyperkeratosis;
hyperpigmented skin; abnormal or diminished syntheses of collagen, glycosaminoglycans, proteoglycans, and elastin; diminished levels of collagen, glycosaminoglycans, proteoglycans, and elastin in the dermis; stretch marks; thinning of skin; loss or reduction of skin resiliency, elasticity, and recoilability; lack of skin resiliency, elasticity, and recoilability, and lack of skin lubricants and luster.
52. The use of claim 51, wherein the composition further comprises (C) a cosmetic, pharmaceutical or other topical agent selected from the group consisting of agents that improve or eradicate age spots, keratoses, and wrinkles; local analgesics and anesthetics;
antiacne agents; antibacterials; antiyeast agents; antifungal agents;
antiviral agents;
antidandruff agents; antidermatitis agents; antihistamine agents; antipruritic agents;
antiemetics; antimotion sickness agents; antiinflammatory agents;
antihyperkeratotic agents;
antiperspirants; antipsoriatic agents; antiseborrheic agents; hair conditioners and hair treatment agents; antiaging and antiwrinkle agents; sunblock and sunscreen agents; skin lightening agents; depigmenting agents; vitamins; corticosteroids; tanning agents; hormones;
retinoids; and topical cardiovascular agents.
53. The use of claim 52, wherein the cosmetic, pharmaceutical or other topical agent is selected from the group consisting of clotrimazole; ketoconazole; miconazole;
griseofulvin;
econazole; metronidazole; hydroxyzine; diphenhydramine; pramoxine; lidocaine;
procaine;
mepivacaine; monobenzone; erythromycin; tetracycline; clindamycin;
meclocycline;

hydroquinone; hydroquinone monoether; minocycline; naproxen; ibuprofen;
theophylline;
cromolyn; albuterol; retinol; retinyl acetate; retinyl palmitate; retinoic acid; 13-cis retinoic acid; hydrocortisone; hydrocortisone 21-acetate; hydrocortisone 17-valerate;
hydrocortisone 17-butyrate; betamethasone valerate; betamethasone dipropionate; triamcinolone acetonide;
fluocinonide; clobetasol propionate; benzoyl peroxide; crotamiton;
propranolol;
promethazine; and salicylic acid.
CA2683980A 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids Expired - Lifetime CA2683980C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2778317A CA2778317C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/227,213 US6159485A (en) 1999-01-08 1999-01-08 N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
US09/227,213 1999-01-08
CA2358457A CA2358457C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2358457A Division CA2358457C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2778317A Division CA2778317C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids

Publications (2)

Publication Number Publication Date
CA2683980A1 true CA2683980A1 (en) 2000-07-13
CA2683980C CA2683980C (en) 2012-08-07

Family

ID=22852222

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2358457A Expired - Lifetime CA2358457C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids
CA2778317A Expired - Lifetime CA2778317C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids
CA2683980A Expired - Lifetime CA2683980C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2358457A Expired - Lifetime CA2358457C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids
CA2778317A Expired - Lifetime CA2778317C (en) 1999-01-08 2000-01-07 Topical composition comprising n-acetylaldosamines or n-acetylamino acids

Country Status (12)

Country Link
US (7) US6159485A (en)
EP (5) EP2080504A2 (en)
JP (2) JP2002534369A (en)
CN (1) CN1336817A (en)
AU (1) AU775209B2 (en)
BR (1) BR0007430A (en)
CA (3) CA2358457C (en)
DE (2) DE60022162T3 (en)
ES (3) ES2248042T5 (en)
HK (1) HK1156853A1 (en)
MX (1) MXPA01006917A (en)
WO (1) WO2000040217A1 (en)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761600B1 (en) * 1998-06-19 2000-03-31 Oreal FOAMING COMPOSITION FOR THE WASHING AND TREATMENT OF HAIR AND / OR SCALP BASED ON AN ACTIVE INGREDIENT, AN ANIONIC SURFACTANT, AN AMPHOTERIC SURFACTANT AND A PROPENETANT
US6808716B2 (en) * 1999-01-08 2004-10-26 Ruey J. Yu N-acetylamino acids, related N-acetyl compounds and their topical use
US6159485A (en) 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
US6413525B1 (en) 1999-05-06 2002-07-02 Color Access, Inc. Methods of exfoliation using N-acetyl glucosamine
FR2794974B1 (en) * 1999-06-16 2001-08-17 Exsymol Sa COSMETIC COMPOSITION FOR SLIMMING BASED ON L-ARGININE, AN ANALOG OF L-ARGININE OR A DERIVATIVE THEREOF, APPLICABLE TOPICALLY
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US7083781B2 (en) 1999-08-19 2006-08-01 Lavipharm S.A. Film forming polymers, methods of use, and devices and applications thereof
WO2002006225A1 (en) * 2000-07-19 2002-01-24 Kyowa Hakko Kogyo Co., Ltd. Preventives or remedies for atopic dermatitis
JP2002128651A (en) * 2000-10-25 2002-05-09 Kose Corp Photoaging inhibitor and skin care preparation characterized by comprising the same
EP1343492B1 (en) * 2000-11-22 2006-02-01 Rxkinetix, Inc. Treatment of mucositis
JP2002193782A (en) * 2000-12-22 2002-07-10 Shiyuu Uemura Keshohin:Kk Skin cosmetic
JPWO2002055074A1 (en) 2001-01-05 2004-05-13 協和醗酵工業株式会社 Prophylactic or therapeutic agent for arthritis
WO2002062341A1 (en) * 2001-02-07 2002-08-15 University Of Florida Method and composition for the control of hair growth
CN1168453C (en) * 2001-02-28 2004-09-29 中国人民解放军第三军医大学 Application of N-acetyl-D-aminoglucose in preparing medicine to prevent and treat motion sickness
NL1017487C2 (en) * 2001-03-02 2002-09-06 Caral B V I O Preparation with polydimethylsiloxane for disorders of nails, cartilage, bones, joints, muscles and tendons.
US20020182237A1 (en) * 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
DE10114561A1 (en) † 2001-03-24 2002-09-26 Wella Ag Creatine, creatinine and/or their salts or derivatives are used in agents for repairing hair or increasing its gloss, volume or combability
AU2002309092A1 (en) * 2001-03-30 2002-10-15 L'oreal Compositions comprising at least one saccharide type compound and their use for the protection and/or repair of hair
US20030017181A1 (en) 2001-05-31 2003-01-23 Rood Gloria A. Dermatological compositions and methods
JP5000049B2 (en) * 2001-08-27 2012-08-15 株式会社ファンケル Anti-aging agent
EP1297830A1 (en) * 2001-09-28 2003-04-02 Flamma Fabbrica Lombarda Ammino Acidi S.p.a. Use of alpha- or beta-amino acids, of the corresponding esters or of dipeptides of these amino acids with histidine derivatives in the prevention or treatment of tissue damage caused by a atmospheric ozone
US20050209131A1 (en) * 2001-11-16 2005-09-22 Singleton Laura C Composition containing peptides complexed with a copper ion
AU2002364897A1 (en) * 2001-11-17 2003-06-10 Maria Martinez-Colon Imiquimod therapies
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
FR2834213B1 (en) * 2001-12-27 2004-06-04 Pharmascience Lab COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ALKANOLAMIDE FOR INHIBITING LANGERHAN CELL MIGRATION, AND USES THEREOF
MC200053A1 (en) * 2002-01-04 2002-07-29 A M Exsymol S Use of L-arginine derivatives as photoprotective agents and optimizing the melanin response in cosmetic compositions
US6869598B2 (en) * 2002-03-22 2005-03-22 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stabilization of sunscreens in cosmetic compositions
AU2003220691A1 (en) * 2002-04-10 2003-10-27 Van Scott, Eugene J. Urea compositions
IL152397A (en) * 2002-10-21 2009-02-11 Hadasit Med Res Service Compositions and compounds for the treatment of hyperglycemia
US7374772B2 (en) * 2002-11-07 2008-05-20 Bommarito Alexander A Topical antifungal treatment
US20080076720A1 (en) * 2003-03-04 2008-03-27 Sancai Xie Personal care compositions having kinetin or zeatin
US20050019356A1 (en) * 2003-07-25 2005-01-27 The Procter & Gamble Company Regulation of mammalian keratinous tissue using N-acyl amino acid compositions
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
DE10316666B4 (en) * 2003-04-10 2015-04-09 Beiersdorf Ag Cosmetic or dermatological preparations with a combination of creatinine with creatine and coenzyme Q10
CA2538352A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize n-acyl-l-aspartic acid
WO2005041870A2 (en) * 2003-10-24 2005-05-12 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
AU2004287448A1 (en) * 2003-10-31 2005-05-19 The Procter & Gamble Company Skin care composition containing dehydroacetic acid and skin care actives
US8652532B2 (en) * 2003-11-21 2014-02-18 Nestec S.A. Food composition comprising glucosamine
KR20120062681A (en) 2003-11-27 2012-06-14 가부시키가이샤 시세이도 Parakeratosis inhibitor and external composition for skin
JP5241058B2 (en) * 2003-11-27 2013-07-17 株式会社 資生堂 Keratinization inhibitor and pore-reducing agent
US20050171194A1 (en) * 2003-12-08 2005-08-04 Yu Ruey J. Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions
DE102004010717A1 (en) * 2004-03-03 2005-09-22 Beiersdorf Ag Cosmetic and/or dermatological preparation, useful as e.g. hair shampoo and to protect skin, hair and nails from sunlight (UV light), comprises polyquaternium-10, quaternized guar and creatine and/or its salts
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2005112948A1 (en) * 2004-05-21 2005-12-01 Tottori University Drug for remedy or treatment of wound
US8338648B2 (en) 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7754875B1 (en) 2004-09-17 2010-07-13 Jfc Technologies, Llc Halide-free glucosamine base-organic acid salt compositions
WO2006054792A1 (en) * 2004-11-19 2006-05-26 Shiseido Company, Ltd. Springiness and stiffness improving agent for hair and cosmetic preparation for hair
US20060127342A1 (en) * 2004-12-09 2006-06-15 Georgia Levis Taurine-based compositions, therapeutic methods, and assays
US20060147504A1 (en) * 2004-12-30 2006-07-06 Bobby Corry Feminine anti-itch cloth
US20060166901A1 (en) * 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
FR2880802B1 (en) * 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT
US8252308B2 (en) * 2005-01-27 2012-08-28 C.B. Fleet Company Inc. Feminine anti-itch gel
US20060211754A1 (en) * 2005-03-16 2006-09-21 Yu Ruey J Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof
US9616011B2 (en) 2005-04-27 2017-04-11 The Procter & Gamble Company Personal care compositions
US20080095732A1 (en) * 2005-04-27 2008-04-24 Rosemarie Osborne Personal care compositions
US20070020220A1 (en) 2005-04-27 2007-01-25 Procter & Gamble Personal care compositions
JP4865251B2 (en) * 2005-05-09 2012-02-01 株式会社 資生堂 Deficiency keratinization inhibitor, pore reducing agent, and composition for external use on skin
FR2885522B1 (en) * 2005-05-13 2020-01-10 Sederma COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING TEPRENONE
US20060263309A1 (en) * 2005-05-17 2006-11-23 Bissett Donald L Regulation of mammalian keratinous tissue using personal care compositions comprising tetrahydrocurcumin
US20070020221A1 (en) * 2005-05-17 2007-01-25 Bissett Donald L Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride
US20060263321A1 (en) * 2005-05-17 2006-11-23 The Procter & Gamble Company Regulation of mammalian keratinous tissue using personal care compositions comprising diethylhexyl syringylidene malonate
JP5014592B2 (en) * 2005-05-25 2012-08-29 株式会社 資生堂 Inadequate keratinization inhibitor, pore reducing agent, rough skin prevention / improving agent
WO2007001904A2 (en) * 2005-06-21 2007-01-04 The Procter & Gamble Company Personal care compositions comprising alpha-glucans and/or beta-glucans
EP1908454A1 (en) * 2005-07-26 2008-04-09 Shiseido Company, Ltd. Wrinkle-preventive/ameliorating agent
FR2890310B1 (en) * 2005-09-06 2009-04-03 Sederma Soc Par Actions Simpli USE OF PROTOBERBERINS AS AGENTS REGULATING THE ACTIVITY OF THE PILOSEBACEE UNIT
JPWO2007034750A1 (en) * 2005-09-22 2009-03-26 株式会社資生堂 Wrinkle improver
EP1940346A2 (en) * 2005-09-30 2008-07-09 The Procter and Gamble Company Composition for regulation of mammalian keratinous tissue
US7501452B2 (en) * 2005-11-30 2009-03-10 Endo Pharmaceuticals Inc. Treatment of xerostomia
US20070196292A1 (en) * 2005-11-30 2007-08-23 Robinson Larry R Personal care composition comprising dehydroacetate salts
US20070196296A1 (en) * 2005-12-13 2007-08-23 Rosemarie Osborne Personal care compositions
CN101330902A (en) * 2005-12-13 2008-12-24 宝洁公司 Personal care compositions comprising PPAR GAMMA antagonists
JP2007197371A (en) * 2006-01-26 2007-08-09 Yaizu Suisankagaku Industry Co Ltd Beautiful skin promoter and beauty and health food
ES2638242T3 (en) * 2006-02-16 2017-10-19 Sederma  KXK polypeptides and their use
US20080031833A1 (en) * 2006-03-13 2008-02-07 Oblong John E Combined energy and topical composition application for regulating the condition of mammalian skin
EP2001558A2 (en) * 2006-03-21 2008-12-17 Henkel AG & Co. KGaA Reductive colour removal
EP2283899B1 (en) * 2006-03-21 2017-07-19 Henkel AG & Co. KGaA Reductive colour removal
FR2900573B1 (en) 2006-05-05 2014-05-16 Sederma Sa NOVEL COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE PEPTIDE CONTAINING AT LEAST ONE BLOCKED AROMATIC CYCLE
FR2901134B1 (en) * 2006-05-19 2008-10-03 Galderma Sa USE OF A COMPOSITION COMPRISING A COMBINATION OF HYDROQUINONE, FLUOCINOLONE ACETONIDE, AND TRETINOINE FOR THE TREATMENT OF CUTANEOUS SIGNALS OF PHOTOVEMENSIONING
CN101489523B (en) 2006-07-25 2012-02-01 萨宝公司 Cosmetic or dermatological preparations comprising N-acetylcysteine
FR2904549B1 (en) * 2006-08-03 2012-12-14 Sederma Sa COMPOSITION COMPRISING SARSASAPOGENIN
US7319157B1 (en) * 2007-02-20 2008-01-15 Multi Formulations Ltd. Creatine-fatty acids
WO2008101310A1 (en) * 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
WO2008101692A2 (en) 2007-02-22 2008-08-28 Beiersdorf Ag Cosmetic and pharmaceutical applications of n-acetylhydroxyproline
US8469621B2 (en) * 2007-02-27 2013-06-25 The Procter & Gamble Company Personal care product having a solid personal care composition within a structure maintaining dispenser
CN101621987B (en) * 2007-02-28 2013-08-21 宝洁公司 Personal care composition comprising botanical extract of ficus benghalensis
US20090017080A1 (en) * 2007-03-15 2009-01-15 Paul Robert Tanner Personal care kit having skin care compositions with a readily perceptible difference
JP2009073806A (en) * 2007-08-27 2009-04-09 Iriya Cosmetics Co Ltd Insulin-like growth factor-1 secretagogue
US9119866B2 (en) * 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
US8546369B2 (en) 2008-05-30 2013-10-01 Northern Innovations Holding Corp. Salts of creatine imino sugar amides
FR2935378B1 (en) * 2008-08-29 2015-03-27 Seppic Sa USE OF N-ACYL AMINOACIDS AS ACTIVE COSMETIC AND PHARMACEUTICAL PRINCIPLES, CAPABLE OF REDUCING THE INFLAMMATORY CONDITION OF SENESCENT REPLICATIVE FIBROBLASTS FROM HUMAN ADULT DERMAS; ANTI-AGE COSMETIC COMPOSITIONS
FR2939799B1 (en) 2008-12-11 2011-03-11 Sederma Sa COSMETIC COMPOSITION COMPRISING ACETYL OLIGOGLUCURONANS.
FR2941232B1 (en) 2009-01-16 2014-08-08 Sederma Sa NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES
EP3744729B1 (en) 2009-01-16 2023-03-01 Sederma Peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
FR2941231B1 (en) 2009-01-16 2016-04-01 Sederma Sa NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES
US9676696B2 (en) 2009-01-29 2017-06-13 The Procter & Gamble Company Regulation of mammalian keratinous tissue using skin and/or hair care actives
FR2944435B1 (en) 2009-04-17 2011-05-27 Sederma Sa COSMETIC COMPOSITION COMPRISING ORIDONIN
FR2945939B1 (en) 2009-05-26 2011-07-15 Sederma Sa COSMETIC USE OF TYR-ARG DIPEPTIDE TO FIGHT SKIN RELEASE.
JP5564205B2 (en) * 2009-06-05 2014-07-30 焼津水産化学工業株式会社 Skin pruritus improving agent
US20100322983A1 (en) * 2009-06-22 2010-12-23 Susan Adair Griffiths-Brophy Personal-Care Composition
CA2769512C (en) 2009-07-29 2019-07-09 Duke University Compositions comprising fp receptor antagonists and their use for inhibiting hair growth
US20110039928A1 (en) 2009-08-13 2011-02-17 Golini Jeffrey M Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition
US20110243876A1 (en) 2010-04-01 2011-10-06 Rajan Keshav Panandiker Organosilicones
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US20110269657A1 (en) 2010-04-28 2011-11-03 Jiten Odhavji Dihora Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US20120172281A1 (en) 2010-07-15 2012-07-05 Jeffrey John Scheibel Detergent compositions comprising microbially produced fatty alcohols and derivatives thereof
US10842728B2 (en) 2010-08-09 2020-11-24 Allele Biotechnology & Pharmaceuticals, Inc. Light-absorbing compositions and methods of use
US9205284B2 (en) 2010-08-09 2015-12-08 Allele Biotechnology & Pharmaceuticals, Inc. Light-absorbing compositions and methods of use
US9737472B2 (en) 2010-08-09 2017-08-22 Allele Biotechnology & Pharmaceuticals, Inc. Light-absorbing compositions and methods of use
WO2012026639A1 (en) * 2010-08-27 2012-03-01 (주)네오팜 Novel compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient
CN104257515B (en) * 2010-10-22 2017-05-03 新钰生技股份有限公司 Glycine derivate having function of inhibiting melanogenesis and whitening composition using same
IT1403257B1 (en) * 2010-12-06 2013-10-17 Intercos Italiana COSMETIC COMPOSITIONS CONTAINING COMPOUNDS WITH ANTI-GLYCATION ACTION, TO BE USED TO PREVENT AND SLOW DOWN THE CUTANEOUS AGING PROCESS
KR101298575B1 (en) * 2011-02-15 2013-08-22 대상 주식회사 The cosmetic composition containing n-acetyl-l-glutamine
US9162085B2 (en) 2011-04-07 2015-10-20 The Procter & Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
MX2013010981A (en) 2011-04-07 2013-10-30 Procter & Gamble Conditioner compositions with increased deposition of polyacrylate microcapsules.
JP5869663B2 (en) 2011-04-07 2016-02-24 ザ プロクター アンド ギャンブルカンパニー Shampoo compositions with increased adhesion of polyacrylate microcapsules
WO2012142474A2 (en) 2011-04-13 2012-10-18 Thermolife International, Llc N-acetyl beta alanine methods of use
JP2014524901A (en) 2011-06-13 2014-09-25 ザ プロクター アンド ギャンブル カンパニー Personal care compositions containing diamide gelling agents and methods of use
CN104039396A (en) 2011-06-13 2014-09-10 宝洁公司 PERSONAL CARE COMPOSITIONS COMPRISING A pH TUNEABLE GELLANT AND METHODS OF USING
CA2839992C (en) 2011-06-20 2016-10-04 The Procter & Gamble Company Personal care compositions comprising shaped abrasive particles
JP5702248B2 (en) * 2011-07-28 2015-04-15 三菱製紙株式会社 Nanofiber, method for forming nanofiber, and method for forming nanofiber aggregate
JP5254417B2 (en) * 2011-10-07 2013-08-07 株式会社 資生堂 Inadequate keratinization inhibitor, pore reducing agent, and rough skin prevention / improving agent
EP3777876B1 (en) 2011-10-28 2023-08-09 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
EP2886163A1 (en) * 2011-12-20 2015-06-24 Oriflame Research and Development Ltd. Compounds with Anti-aging activities
CA2863681A1 (en) 2012-02-14 2013-08-22 The Procter & Gamble Company Topical use of a skin-commensal prebiotic agent and compositions containing the same
US20130243834A1 (en) 2012-03-19 2013-09-19 The Procter & Gamble Company Cross linked silicone copolmyer networks in a thickened aqueous phase
WO2013142301A2 (en) 2012-03-19 2013-09-26 The Procter & Gamble Company Superabsorbent polymers and silicone elastomer for use in hair care compositions
US9549891B2 (en) 2012-03-19 2017-01-24 The Procter & Gamble Company Superabsorbent polymers and sunscreen actives for use in skin care compositions
US9271912B2 (en) 2012-06-13 2016-03-01 The Procter & Gamble Company Personal care compositions comprising a pH tuneable gellant and methods of using
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
FR2996128B1 (en) * 2012-09-28 2015-01-02 Inneov Lab USE OF AN ASSOCIATION OF TAURINE OR ONE OF ITS DERIVATIVES, AND GRAPE EXTRACT FOR IMPROVING THE QUALITY OF NAILS.
GB201220354D0 (en) * 2012-11-12 2012-12-26 Medpharm Ltd Dermal compositions
US20140178314A1 (en) 2012-12-19 2014-06-26 The Procter & Gamble Company Compositions and/or articles with improved solubility of a solid active
US8865700B2 (en) 2012-12-20 2014-10-21 Avon Products, Inc. Collagen stimulators and their use in the treatment of skin
US8901122B2 (en) 2012-12-20 2014-12-02 Avon Products, Inc. Collagen stimulators and their use in the treatment of skin
US9445981B2 (en) * 2012-12-20 2016-09-20 Avon Products, Inc PLOD-2 stimulators and their use in the treatment of skin
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
US20140314697A1 (en) * 2013-04-18 2014-10-23 Corum Inc. Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof
CA2912226A1 (en) 2013-05-10 2014-11-13 The Procter & Gamble Company Modular emulsion-based product differentiation
CA2910384A1 (en) 2013-05-10 2014-11-13 The Procter & Gamble Company Modular emulsion-based product differentiation
JP6186076B2 (en) 2013-05-10 2017-08-23 ザ プロクター アンド ギャンブル カンパニー Differentiation of standard emulsion products
WO2015099755A1 (en) * 2013-12-27 2015-07-02 Colgate-Palmolive Company Prebiotic oral care methods using a saccharide
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
JP2017511347A (en) * 2014-04-24 2017-04-20 ザ プロクター アンド ギャンブル カンパニー Scalp care composition
JP2017531682A (en) * 2014-10-23 2017-10-26 アムジエン・インコーポレーテツド Reduced viscosity of pharmaceutical preparations
US9883996B2 (en) 2014-11-14 2018-02-06 The General Hospital Corporation Methods and compositions for enhancing skin pigmentation
PL3226854T3 (en) * 2014-12-04 2020-08-24 Professional Dietetics International S.r.l. in forma abbreviata P.D. INT. S.R.L. Aminoacid-based composition for fibroelastin recovery in dermal connective tissues
US10682324B2 (en) 2015-01-27 2020-06-16 Florengale, Llc Healing topical composition
JP6692673B2 (en) * 2015-06-01 2020-05-13 株式会社コーセー Method for evaluating changes in intercellular lipids due to drugs, method for screening drugs, method for evaluating intercellular lipids
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
WO2017004108A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Superabsorbent polymers and starch powders for use in skin care compositions
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
WO2017017585A1 (en) * 2015-07-26 2017-02-02 Mohan M Alapati Compound, composition and uses thereof
JP6346596B2 (en) * 2015-08-31 2018-06-20 株式会社ミルボン First agent for hair deformation and hair deformation treatment method
CN108348456B (en) 2015-10-30 2021-09-17 亭铂医药有限责任公司 Isotretinoin formulations and uses and methods thereof
JP6159382B2 (en) * 2015-12-24 2017-07-05 花王株式会社 Oral UV resistance improver
EP3411243B1 (en) 2016-02-05 2021-12-01 The Procter & Gamble Company Methods of applying compositions to webs
US10195091B2 (en) 2016-03-11 2019-02-05 The Procter & Gamble Company Compositioned, textured nonwoven webs
WO2018049108A1 (en) 2016-09-09 2018-03-15 The Procter & Gamble Company Systems and methods of applying compositions to webs and webs thereof
US10543240B2 (en) 2016-12-12 2020-01-28 Johnson & Johnson Consumer Inc. Topical composition containing glycerin and yeast extract
US11219589B2 (en) 2017-02-13 2022-01-11 Conopco, Inc Method of strengthening oxidatively-treated hair
MX2019009527A (en) * 2017-02-13 2019-09-23 Unilever Nv Method of strengthening hair.
WO2019103506A2 (en) * 2017-11-24 2019-05-31 전북대학교 산학협력단 Composition for treating atopy or pruritus comprising n-acetyl or n-acyl amino acid
KR102139678B1 (en) * 2017-11-24 2020-07-31 전북대학교 산학협력단 A Composition for Treating Atopy or Pruritus Comprising N-acetyl or N-acyl amino acid
WO2019214965A1 (en) 2018-05-10 2019-11-14 Unilever Plc Method of repairing oxidatively treated hair
JP7048051B2 (en) * 2018-07-11 2022-04-05 正徳 染井 Atopic dermatitis remedy to reduce itching
US11166997B2 (en) 2018-07-27 2021-11-09 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
WO2020021481A1 (en) 2018-07-27 2020-01-30 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating the eye
AU2019311849B2 (en) 2018-07-27 2023-06-08 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11045416B2 (en) 2018-08-30 2021-06-29 Johnson & Johnson Consumer Inc. Topical compositions comprising Pichia anomala and retinol
US11110051B2 (en) * 2018-08-30 2021-09-07 Johnson & Johnson Consumer Inc. Topical compositions comprising Pichia anomala and n-acetyl glucosamine
CN110870869A (en) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 Pharmaceutical composition comprising carbohydrate nutrients and conventional ineffective compounds and use thereof
CN110870860A (en) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 Pharmaceutical composition comprising amino acid nutrients and conventional ineffective compounds and use thereof
CN110870914A (en) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 Use of amino acid nutrients and pharmaceutical compositions containing same
WO2020089236A1 (en) 2018-11-02 2020-05-07 Unilever Plc Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
EP3914242A4 (en) * 2019-01-23 2023-02-01 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
MX2022000347A (en) 2019-07-12 2022-02-03 Unilever Ip Holdings B V Bioenergetic combinations and methods of using same.
EP3996664A1 (en) 2019-07-12 2022-05-18 Unilever Global IP Limited Stabilization of resorcinol compounds in cosmetic compositions
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
US20220323388A1 (en) * 2021-04-01 2022-10-13 Yu Ruey J Creatine, its derivatives, compositions and methods of use thereof
WO2023192538A1 (en) 2022-03-31 2023-10-05 Galderma Holding SA Personal care compositions for sensitive skin and methods of use

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792346C3 (en) * 1968-08-22 1980-10-23 Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien) Pharmaceutical preparation for the treatment of degenerative joint diseases
US3856934A (en) * 1970-06-24 1974-12-24 A Kligman Skin depigmentation
US4016287A (en) * 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
US4165385A (en) * 1973-05-29 1979-08-21 Dianis Creations, Inc. Water-in-oil emulsion for skin moisturizing
DE2330927C2 (en) * 1973-06-18 1983-11-10 Ideal-Standard Gmbh, 5300 Bonn Sanitary water valve made of plastic
FR2244541A1 (en) * 1973-08-01 1975-04-18 Fabre Sa Pierre Amino acid salts of quinine alkaloids - as phospho-lipase inhibitors and anti-acne agents
US3932622A (en) * 1974-01-11 1976-01-13 General Foods Corporation Skin moisturizer
AR207237A1 (en) * 1974-02-25 1976-09-22 Thomas A PROCEDURE FOR OBTAINING SOLUBLE LYOPHILIZED STABLE BIOLOGICAL EXTRACTS CONSTITUTED BY THERMORE RESISTANT PROTEIN COMPLEXES
JPS6039042B2 (en) * 1976-04-10 1985-09-04 田辺製薬株式会社 1st liquid for permanent wave
US4176197A (en) * 1978-02-03 1979-11-27 Dominion Pharmacal, Inc. Method for treating acne vulgaris
CA1156028A (en) 1979-11-09 1983-11-01 Wolfgang K. F. Otto Mechanical surface finishing apparatus, process and product
JPS5679618A (en) * 1979-11-30 1981-06-30 Tanabe Seiyaku Co Ltd Liquid for permanent wave
JPS56155298A (en) * 1980-05-02 1981-12-01 Tanabe Seiyaku Co Shampoo composition
EP0057323A3 (en) * 1980-12-24 1983-05-18 Warner-Lambert Company Anticaries composition
US4603146A (en) 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
JPS5913708A (en) * 1982-07-14 1984-01-24 Shiseido Co Ltd Cosmetic
DE3435842A1 (en) * 1984-09-29 1986-04-10 Wella Ag Use of N- alpha -acetyllysinamide in skin treatment compositions for increased bronzing of the skin
FR2572399B1 (en) 1984-10-31 1987-01-16 Panmedica Sa NOVEL ADAMANTANAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
JPH0645524B2 (en) * 1985-03-13 1994-06-15 岩瀬コスファ株式会社 External skin preparation
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
IT1183530B (en) * 1985-03-29 1987-10-22 Monteluos S P A COMPOSITIONS FOR COSMETICS INCLUDING PERFLUOROPOLYETERS
US4762822A (en) * 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
GB2180153A (en) * 1985-09-10 1987-03-25 Rory Ltd Compositions containing acetylcysteine
US4827016A (en) * 1985-09-16 1989-05-02 Morgan Lee R Method and compounds for reducing dermal inflammations
US4708965A (en) * 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
US4772591A (en) * 1985-09-25 1988-09-20 Peritain, Ltd. Method for accelerated wound healing
GB8524807D0 (en) * 1985-10-08 1985-11-13 Hendry N G C Tissue growth regulation
DE3602670A1 (en) * 1986-01-29 1987-07-30 Speck Ulrich USE OF N-ACETYLGLUCOSAMINE FOR THE THERAPY OF DEGENERATIVE JOINT PROCESSES AND RELATED DISEASES
US5300494A (en) * 1986-06-06 1994-04-05 Union Carbide Chemicals & Plastics Technology Corporation Delivery systems for quaternary and related compounds
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5385938B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5547988B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Alleviating signs of dermatological aging with glycolic acid lactic acid or citric acid
EP0281812A1 (en) * 1987-02-18 1988-09-14 Milor Scientific, Ltd. Composition for treatment of acne
US5258391A (en) 1987-05-15 1993-11-02 Scott Eugene J Van Phenyl alpha acyloxyalkanoic acids, derivatives and their therapeutic use
US5643949A (en) 1987-05-15 1997-07-01 Tristrata, Inc. Phenyl alpha acyloxyalkanoic acids, derivatives and their therapeutic use
US5641475A (en) 1987-05-15 1997-06-24 Tristrata, Inc. Antiodor, antimicrobial and preservative compositions and methods of using same
DE3867710D1 (en) * 1987-06-01 1992-02-27 Keikichi Sugiyama COMPOSITION FOR APPLICATION ON HAIR AND SCALP.
FR2619711B1 (en) * 1987-09-02 1991-01-11 Givaudan La Virotte Cie Ets COSMETIC APPLICATION OF PROLINE DERIVATIVES, HYDROXYPROLINE AND / OR MIXTURE OF AMINO ACIDS RESULTING FROM COLLAGEN HYDROLYSIS
JP2557240B2 (en) * 1987-12-21 1996-11-27 雪印乳業株式会社 Skin anti-aging agent
AU2971689A (en) * 1988-02-11 1989-08-17 Estee Lauder Inc. Tanning compositions and their use
FR2609397B1 (en) 1988-02-23 1991-12-13 Serobiologiques Lab Sa USE OF A CARBOHYDRATE SUBSTANCE OR COMPOSITION AS AN ACTIVE INGREDIENT OF A DERMATOLOGICAL AND / OR COSMETOLOGICAL AND / OR PHARMACEUTICAL AND / OR CELL STIMULANT COMPOSITION, AND COMPOSITION CONTAINING SUCH A CARBON SUBSTANCE OR COMPOSITION
GB8918709D0 (en) * 1989-08-16 1989-09-27 Unilever Plc Cosmetic composition
US5470567A (en) * 1989-08-24 1995-11-28 Bristol Myers Squibb Company Synergistic skin depigmentation composition
JP2886591B2 (en) * 1990-01-27 1999-04-26 協和醗酵工業株式会社 Cosmetics
IL97012A0 (en) * 1990-01-30 1992-03-29 Gist Brocades Nv Topical preparations for treating human nails
JPH0578243A (en) * 1990-12-11 1993-03-30 Shiseido Co Ltd Antipruritic agent and antipruritic composition
EP0514576A1 (en) * 1991-05-24 1992-11-25 Societe Des Produits Nestle S.A. Oil-soluble antioxidant mixture
US5296500A (en) * 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
GB9118866D0 (en) * 1991-09-04 1991-10-23 Unilever Plc Cosmetic composition
FR2688136B1 (en) * 1992-03-03 1995-06-09 Oreal COSMETIC COMPOSITION CONTAINING MELANIC PIGMENTS IN ASSOCIATION WITH CERTAIN TOCOPHEROLS, AND METHOD FOR PROTECTING THE SKIN, HAIR, MUCOSA AND COSMETIC COMPOSITIONS.
AU2771792A (en) * 1992-03-31 1993-11-08 Kyowa Hakko Kogyo Co. Ltd. Novel cosmetic
CA2134979A1 (en) * 1992-05-05 1993-11-11 Spencer Guang Lin Acne treating composition
US5286480A (en) 1992-06-29 1994-02-15 The Procter & Gamble Company Use of N-acetylated amino acid complexes in oral care compositions
US5677285A (en) * 1992-08-03 1997-10-14 Fidia S.P.A. Derivatives of neuraminic acid
DE4228455A1 (en) 1992-08-26 1994-09-15 Beiersdorf Ag Cosmetic and dermatological sunscreen formulations containing thiols and / or thiol derivatives
ES2110213T3 (en) * 1992-12-09 1998-02-01 Kyowa Hakko Kogyo Kk DERIVED FROM N-ACILGLUTAMINA.
ES2101263T3 (en) * 1993-02-19 1997-07-01 Howard Green COMPOSITIONS CONTAINING CORNEOCYTE PROTEINS.
JPH11501611A (en) 1993-06-18 1999-02-09 アークチュラス、ファーマシューティカル、コーポレーション Methods for treating hyperkeratosis and protease-mediated diseases
FR2714597B1 (en) * 1993-12-30 1996-02-09 Oreal Moisturizing composition for the simultaneous treatment of the superficial and deep layers of the skin, its use.
FR2715565B1 (en) * 1994-01-31 1996-03-15 Oreal Stabilized cosmetic or dermatological composition containing several precursors of the same active ingredient to maximize its release, its use.
US5468476A (en) * 1994-03-16 1995-11-21 Ahluwalia; Gurpreet S. Reduction of hair growth
US5451405A (en) * 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
JP3650400B2 (en) * 1994-06-30 2005-05-18 協和醗酵工業株式会社 Hair restorer
JP3760287B2 (en) * 1994-11-24 2006-03-29 株式会社コーセー Cosmetics
US5472698A (en) * 1994-12-20 1995-12-05 Elizabeth Arden Co., Division Of Conopco, Inc. Composition for enhancing lipid production in skin
JP3485375B2 (en) * 1995-02-17 2004-01-13 株式会社資生堂 External preparation for skin
US5866142A (en) * 1995-07-20 1999-02-02 Riordan; Neil H. Skin treatment system
US5776920A (en) * 1995-08-02 1998-07-07 Quarles; Ruth Method for treatment of psoriasis
FR2739556B1 (en) 1995-10-04 1998-01-09 Oreal USE OF CARBOHYDRATES TO PROMOTE SKIN DEQUAMATION
US5733535A (en) * 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
US5652273A (en) * 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
GB9606429D0 (en) * 1996-03-27 1996-06-05 Boots Co Plc Pharmaceutical compositions
JPH09255526A (en) * 1996-03-27 1997-09-30 Shiseido Co Ltd Cosmetic for preventing aging
US5728371A (en) * 1996-04-29 1998-03-17 L'oreal, S.A. Skin protection, fragrance enhancing and vitamin delivery composition
JPH09323915A (en) * 1996-06-05 1997-12-16 Ichimaru Pharcos Co Ltd Melanin generation inhibitor consisting of n-acetylthyrosine derivative as active ingredient and application of the same to skin preparation for external use and bath agent
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
CN1161198A (en) * 1996-10-29 1997-10-08 贾增申 External ointment for eliminating wrinkle and scar on skin
JPH10163110A (en) * 1996-11-27 1998-06-19 Kyocera Corp Semiconductor device
IT1288257B1 (en) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De COMPOSITION FOR COSMETIC, PHARMACEUTICAL OR DIETETIC USE BASED ON AN AMINO SUGAR AND / OR A POLYHYDROXYL ACID
CN1067246C (en) 1996-12-27 2001-06-20 中国人民解放军第三军医大学 Application of N-aceto-D-aminoglucose for preparing skin sanitary article preparation
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
ES2221176T3 (en) * 1997-05-21 2004-12-16 Bio Minerals N.V. USE OF GLUCOSAMINE AND GLUCOSAMINE DERIVATIVES FOR QUICK RELIEF OF PICOR OR LOCATED PAIN.
US6149924A (en) * 1998-07-20 2000-11-21 Biomed Research & Technologies, Inc. Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
US9616534B2 (en) 2013-11-25 2017-04-11 Invent-A-Part Modular structures for motion stages

Also Published As

Publication number Publication date
WO2000040217B1 (en) 2000-10-05
ES2248042T3 (en) 2006-03-16
EP1570840A2 (en) 2005-09-07
EP1143925B1 (en) 2005-08-24
EP2080504A2 (en) 2009-07-22
DE60041934D1 (en) 2009-05-14
JP2002534369A (en) 2002-10-15
EP1570840B1 (en) 2009-04-01
US6159485A (en) 2000-12-12
CA2778317C (en) 2014-09-16
WO2000040217A1 (en) 2000-07-13
EP1570840A3 (en) 2005-11-16
AU2408000A (en) 2000-07-24
EP2311452B9 (en) 2014-12-24
USRE41339E1 (en) 2010-05-18
EP2311452B1 (en) 2014-04-02
EP1143925A1 (en) 2001-10-17
EP1143925B2 (en) 2011-01-26
JP2012072172A (en) 2012-04-12
ES2325160T3 (en) 2009-08-27
EP2311452B2 (en) 2020-12-30
EP2311452A1 (en) 2011-04-20
DE60022162T2 (en) 2006-03-23
AU775209B2 (en) 2004-07-22
US6524593B1 (en) 2003-02-25
ES2477556T3 (en) 2014-07-17
USRE41278E1 (en) 2010-04-27
USRE44017E1 (en) 2013-02-19
EP1639994A2 (en) 2006-03-29
USRE44302E1 (en) 2013-06-18
CA2358457A1 (en) 2000-07-13
DE60022162T3 (en) 2011-09-29
DE60022162D1 (en) 2005-09-29
BR0007430A (en) 2001-10-16
USRE42902E1 (en) 2011-11-08
CA2778317A1 (en) 2000-07-13
MXPA01006917A (en) 2003-06-04
CN1336817A (en) 2002-02-20
HK1156853A1 (en) 2012-06-22
CA2358457C (en) 2010-03-23
ES2248042T5 (en) 2011-06-03
CA2683980C (en) 2012-08-07

Similar Documents

Publication Publication Date Title
CA2683980A1 (en) Topical composition comprising n-acetylaldosamines or n-acetylamino acids
US5877212A (en) Molecular complex and control-release of alpha hydroxyacids
US5889054A (en) Method of using beta hydroxy acids for treating wrinkles
US5665776A (en) Additives enhancing topical actions of therapeutic agents
US20040033963A1 (en) Urea composition
US6051609A (en) Additives enhancing the effect of therapeutic agents
US20030229141A1 (en) N-acetyl cysteine and its topical use
AU2002350255A1 (en) Compositions comprising phenyl-glycine derivatives
US6808716B2 (en) N-acetylamino acids, related N-acetyl compounds and their topical use
MXPA99009504A (en) Molecularcomplex and control-release of alpha hydroxyacids

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200107